Assessing the economic value of anti-aging drugs
In collaboration with the Buck Institute for Research on Aging, HSR's health economic experts are assessing the value of a new health technology which delays aging and age-related degenerative diseases. 'Anti-aging' drugs are a new line of therapy which improves healthy life and potentially lead to relative compression of morbidity. These drugs potentially slow physiological aging and many of the correlated degenerative and chronic diseases. From a societal perspective, an anti-aging drug would not only improve citizens' health outcomes but also productivity and economic growth. Therefore, assessing the economic value of these benefits will shed a light on the importance of investing in anti-aging research and urge policymakers to enact required policy reforms to insure efficient and equitable access to anti-aging medicines.